Check for updates

RESEARCH ARTICLE

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies [version 1; peer review: 1 approved, 1 approved with reservations]

Binh Phong^{1,2}, Lawrence P. Kane¹

¹Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, USA

²Immunology Graduate Program, University of Pittsburgh School of Medicine, Pittsburgh, USA

V1 First published: 01 Mar 2016, 5:251
<https://doi.org/10.12688/f1000research.8132.1>

Latest published: 08 Jul 2016, 5:251
<https://doi.org/10.12688/f1000research.8132.2>

Abstract

Polymorphisms in the *T cell (or transmembrane) immunoglobulin and mucin domain 1 (TIM-1)* gene, particularly in the mucin domain, have been associated with atopy and allergic diseases in mice and human. Genetic- and antibody-mediated studies revealed that Tim-1 functions as a positive regulator of Th2 responses, while certain antibodies to Tim-1 can exacerbate or reduce allergic lung inflammation. Tim-1 can also positively regulate the function of B cells, NKT cells, dendritic cells and mast cells. However, the precise molecular mechanisms by which Tim-1 modulates immune cell function are currently unknown. In this study, we have focused on defining Tim-1-mediated signaling pathways that enhance mast cell activation through the high affinity IgE receptor (FcεRI). Using a Tim-1 mouse model lacking the mucin domain (Tim-1^{Dmucin}), we show for the first time that the polymorphic Tim-1 mucin region is dispensable for normal mast cell activation. We further show that Tim-4 cross-linking of Tim-1 enhances select signaling pathways downstream of FcεRI in mast cells, including mTOR-dependent signaling, leading to increased cytokine production but without affecting degranulation.

Keywords

Tim-1 , Tim-4 , mast cells , phosphorylation , ribosomal S6

Open Peer Review

Approval Status

	1	2
version 2		
(revision)
08 Jul 2016
version 1		
01 Mar 2016

1. **Avery August**, Cornell University, Ithaca, USA

2. **Bridget S Wilson**, University of New Mexico, Albuquerque, Mexico

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Lawrence P. Kane (lkane@pitt.edu)

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by PHS grant R56AI067544 to LPK.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2016 Phong B and Kane LP. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Phong B and Kane LP. **Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies [version 1; peer review: 1 approved, 1 approved with reservations]** F1000Research 2016, 5:251
<https://doi.org/10.12688/f1000research.8132.1>

First published: 01 Mar 2016, 5:251 <https://doi.org/10.12688/f1000research.8132.1>

Introduction

T-cell immunoglobulin and mucin domain (TIM)-1 belongs to a family of type I transmembrane proteins with essential roles in immune regulation. Tim-1 has an N-terminal IgV domain, a mucin-like domain with multiple potential sites for O-linked glycosylation, followed by a stalk domain with potential N-linked glycosylation sites, a transmembrane domain, and a short cytoplasmic tail. Tim-1 was initially identified as a cellular receptor for hepatitis A virus (HAVCR1)¹. The *TIM-1* gene was positionally cloned from a locus on the same chromosome but distinct from the *IL-4* gene cluster that is commonly associated with Th2-biased immune responses². Polymorphisms in murine Tim-1 are associated with susceptibility to airway hyper-reactivity (AHR), a hallmark of asthma, and increased Th2 cytokine production³. Similarly, polymorphisms in human TIM-1 have been linked to atopic diseases including asthma, allergic rhinitis and atopic dermatitis³. The atopy connection is particularly intriguing since genetic variations in human TIM-1 modify susceptibility or resistance to allergy, but only in individuals seropositive for HAV⁴. These findings suggested that Tim-1 has a role in regulation of immune responses to atopic diseases.

Mechanistically, Tim-1 was shown to co-stimulate T effector cell proliferation, with preferential effects on Th2 cytokine production. Thus, the high affinity agonistic monoclonal antibody (mAb) 3B3 was reported to inhibit the induction of respiratory tolerance in an AHR model⁵, and to enhance both T cell proliferation and cytokine production *in vitro* and *in vivo*^{5,6}. Antibodies recognizing distinct epitopes of Tim-1 either enhanced or attenuated lung inflammation⁷. We further showed that ectopic expression of Tim-1 in T cells stimulated *in vitro* under “neutral” conditions promoted generation of more IL-4- rather than INF- γ production⁶. Tim-1 can also enhance NFAT/AP-1-dependent transcription in T cells activated by TCR crosslinking, suggesting that Tim-1 functions as a co-stimulatory molecule for T cell activation⁸. Similarly, co-stimulatory function of Tim-1 was also observed after interaction of Tim-1 with its ligand Tim-4, which is primarily expressed on APCs^{9,10}.

Regarding signaling pathways coupled to Tim-1, we showed that tyrosine 276 in the cytoplasmic tail of Tim-1 could be phosphorylated in an Lck-dependent manner. This allows for recruitment of the p85 α and β subunits of the PI3K, leading to activation of the downstream kinase Akt and subsequent activation of the transcription factors NFAT and AP-1⁸. Administration of the agonistic Tim-1 antibody 3B3 induces expression of early activation markers CD69 and CD25 as well as IL-2 production⁸. Other groups have demonstrated that ligation of Tim-1 by Tim-4 can activate the ERK/MAPK pathway and enhance T cell survival by up-regulating the anti-apoptotic protein Bcl-x_L⁹. Additional studies revealed that Tim-1 could co-cap with CD3 on human T cells¹¹. Tim-1 ligation on T cells has also been reported to induce tyrosine phosphorylation of the linker for activation of T cells (LAT) and the TCR-proximal Syk family tyrosine kinase Zap70⁹. Taken together, these findings suggested that Tim-1 may interact with proximal TCR signaling complexes.

In addition to T cells, Tim-1 also has regulatory functions on other non-immune and immune cell types. Tim-1, also known as kidney injury molecule (KIM)-1, is upregulated on renal proximal tubules

and shed upon acute renal failure¹². Apoptotic cell recognition by Tim-1, specifically on natural killer T (NKT) cells, may induce AHR in response to respiratory syncytial virus- or ozone-induced experimental asthma¹³. Tim-1 has recently been shown to be expressed by IL10-secreting regulatory B cells and Tim-1 signaling is required for the induction and maintenance of these cells^{14,15}. Specifically, the Tim-1 mucin domain is required for IL-10 production in response to phosphatidylserine (PS) binding and allograft tolerance^{14,15}. Tim-1 is also constitutively expressed on bone marrow-derived (BMMC) and peritoneal (PMC) mast cells. Cross-linking of Tim-1 by Tim-4 enhanced IgE plus antigen-stimulated (IgE/Ag) production of Th2 type cytokines¹⁶. However, the mechanisms by which Tim-1 modulates mast cell functional responses are currently unknown.

Mast cells are among the first responders of immune responses against pathogens and allergens. They have the capacity to secrete a multitude of pro- and anti-inflammatory factors that regulate allergic inflammation, pathogen defense, and anti-tumor immunity¹⁷. Given the genetic and functional connection of Tim-1 to allergy and hypersensitivity and the sentinel role of mast cells in atopy, it is important to determine how Tim-1 signaling contributes to the high affinity Fc receptor for IgE (Fc ϵ RI)-mediated mast cell activation. Here we demonstrate that Tim-1 promotes NF- κ B and NFAT/AP1 transcriptional activation, leading to enhanced IL-6 promoter activation and cytokine production in IgE/Ag-stimulated mast cells. Using BMDCs generated from a mouse strain lacking the Tim-1 mucin domain (Tim1 ^{Δ mucin}), we show that this co-stimulatory effect is independent of the Tim-1 mucin domain. Finally, we show that Tim-1, in contrast with Tim-3, acts more distal to Fc ϵ RI to enhance S6 activation, without affecting proximal Fc ϵ RI signaling. Overall, our findings provide a mechanistic explanation for the co-stimulatory effects of Tim-1 signaling on Fc ϵ RI-mediated mast cell activation.

Methods

Antibodies and reagents

Monoclonal anti-dinitrophenyl (DNP), IgE isotype, clone SPE-7 (Cat No. D8406), DNP₃₂-HSA (Cat No. A6661), anti-FLAG M2 antibody (Cat No. F1804), cyclosporine A (Cat No. C1832), and 4-Nitrophenyl N-acetyl- β -D-glucosaminide (pNAG) (Cat No. N9376) were purchased from Sigma-Aldrich (St. Louis, MO). DNP₅-BSA (Cat No. D5050) was from Biosearch Technologies (Petaluma, CA). Monoclonal antibodies to murine Tim-1 (3B3, RMT1-10, 5G5, 5F12) and purified Tim4-Fc were obtained from Vijay Kuchroo (Harvard Medical School). Human IgG as isotype control for Tim4-Fc was purchased from Jackson ImmunoResearch Laboratories (Cat No. 009-000-003, West Grove, PA). Monoclonal antibodies to BALB/c Tim-1 (1H9, 3A2, 4A2, 4B2, 4G8, 5D1) were originally developed at Biogen and were obtained under an MTA with CoStim Pharmaceuticals (Cambridge, MA). Purified rat IgG2a as isotype control for Tim-1 antibodies was purchased from eBioscience (Cat No. 14-4321-85, San Diego, CA). Phospho-specific antibody to ERK (T202/Y204) was from BD Biosciences (20 μ l per test), (Cat No. 612566, San Jose, CA). Phospho-specific antibodies to Syk (Y519/520) (1:400, Cat No. 2710), and S6 (S235/236), (1:150, Cat No. 4851) were obtained from Cell Signaling Technology (Danvers, MA). Anti-mouse Fc block (2.4G2) was purchased from BD Biosciences (Cat No. 553141, San Jose, CA).

IL-6 luciferase reporter constructs were obtained from Sarah Gaffen (University of Pittsburgh), originally from Oliver Eickelberg (Helmholtz Zentrum Munchen).

Mice

All studies were performed in accordance with University of Pittsburgh Institutional Animal Care and Use Committee procedures. Specifically, mice were housed four males or five females per polycarbonate cage in a 12-hour light/dark cycle. Food and water were provided *ad libitum*. Cages and bedding were changed every seven days. Mutant mice lacking Tim-1 mucin domain (Tim-1^{Δmucin}) were obtained from David Rothstein (University of Pittsburgh), and were originally from Vijay Kuchroo (Harvard Medical School). Age- and sex-matched wild-type C57BL/6 were purchased from the Jackson Laboratory (Bar Harbor, ME) as control.

BMMC and mast cell line culture

Bone marrow cells from C57BL/6 Tim-1 wild-type (WT) and mutant (Tim-1^{Δmucin}) were generated as described previously¹⁸. MC/9 mast cells were cultured in DMEM supplemented with 10% BGS, 2-ME, Pen/Strep with Glutamine, and 10% IL3-conditioned media.

BMMC stimulation, cytokine secretion, and phospho-flow cytometry

BMMCs (1×10^5 or 1×10^6 cells for cytokine measurement and 3×10^5 cells for phospho-flow) were sensitized overnight with 1 μ g/ml IgE without IL-3 conditioned media. Cells were stimulated with DNP₃₂-HSA or DNP₅-BSA. Six or twenty-four hours post stimulation, supernatants were collected and assayed for murine IL-6 and TNF- α by ELISA (BioLegend). For phospho-flow staining, stimulated cells were fixed in 1.5% paraformaldehyde for ten minutes at room temperature and permeabilized with ice cold methanol for thirty minutes. Incubation with phospho-specific antibodies were performed per manufacturer's instructions. Flow acquisition was performed on Fortessa or LSRII (BD Biosciences), and data were analyzed using FlowJo software version 8.7 (Tree Star).

Measurement of beta-hexosaminidase release

BMMCs (2.5×10^5 cells) were sensitized and subsequently stimulated for thirty minutes in Tyrode's buffer (135mM NaCl, 5mM KCl, 5.6mM glucose, 1.8mM CaCl₂, 1mM MgCl₂, 20mM HEPES, and 0.5mg/ml BSA). Supernatants (stimulated release) were collected and cells were lysed (content) with 0.5% Triton-X100 in PBS for fifteen minutes on ice. Content and stimulated release fractions were incubated with 1mM pNAG substrate for 1 hour at 37°C. Carbonate buffer (0.1M, pH 9.0) was added to stop reaction and absorbance was obtained at 405nm on a plate reader (BioTek ELx808). Percentage of beta-hexosaminidase release was calculated as $(\text{release}^{\text{stimulated}}/\text{content}^{\text{total}}) \times 100$.

Mast cell degranulation assay by Annexin V-based flow cytometry

Degranulation was measured as described previously^{18,38}. Briefly, BMMCs were loaded with 0.1 μ M of LysoTracker Deep Red (Invitrogen) for thirty minutes at 37°C prior to sensitization with 0.5 μ g/ml IgE for 1 hour. Ninety minutes after antigen cross-linking by DNP₃₂-HSA, cells were collected and stained with Annexin V

(BioLegend). %degranulation was determined as percentage of BMMCs that is AnnexinV⁺LysoTracker^{lo}. Flow acquisition was performed on Fortessa or LSRII (BD Biosciences), and data were analyzed using FlowJo software version 8.7 (Tree Star).

Transcriptional reporter luciferase assays

MC/9 mast cells (15×10^6) were transfected with 15 μ g of IL6-luc, NF- κ B-luc, or NFAT/AP1-luc with 5 μ g of pCDEF3 (empty vector), FLAG-tagged Tim-1 full length (FL), Tim-1 cytoplasmic deletion (Δ cyto), or Tim-1 tyrosine mutant (Y276F). Electroporation was performed at 290V, 950 μ F using a Gene Pulser II apparatus (Bio-Rad). Cells were collected twenty-four hours post-transfection and stimulated with 0.5 μ g/ml IgE and 30 ng/ml or 100 ng/ml of DNP₃₂-HSA as antigen for six hours. Luciferase assays were performed as previously described³⁹.

Statistical analysis

All statistical analyses was performed using Prism version 6.0 (GraphPad Software). Paired, unpaired, two-tailed Student's t-test, one-way and two-way ANOVA with multiple comparison were used for data analysis and calculation of p values, as appropriate.

Results

Dataset 1. Raw data for Figures 1–5 in 'Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies'

<http://dx.doi.org/10.5256/f1000research.8132.d114870>

Tim1-Tim4 interaction enhances mast cell cytokine production without affecting degranulation

Mast cells constitutively express surface Tim-1 and Tim-3, but not Tim-2 or Tim-4¹⁶. Tim-1 cross-linking by Tim4-Fc was shown to enhance cytokine production in a dose-dependent manner without affecting degranulation¹⁶. We observed similar effects of Tim4-mediated IL-6 production in IgE/Ag-stimulated BMMCs (Figure 1B). In addition, we quantified the degranulation response by measuring beta-hexosaminidase release as well as with a flow cytometry-based assay that tracks both Annexin V binding to exposed PS and loss of LysoTracker staining, due to granule release (AnnexinV+LysoTracker^{lo}). The latter method has the advantage of a high signal-to-noise ratio, and as such has been a robust assay for evaluating IgE/Ag-stimulated mast cell degranulation¹⁸. Thus, we showed that varying the concentration of Tim-4, along with sub-optimal antigen concentration to observe potential co-stimulation, did not have an effect on the immediate degranulation response (Figure 1C–D). These results suggest that Tim-1 ligation by Tim-4 can exert differential effects on the immediate degranulation response, vs. late-phase cytokine production.

Antigen valency and concentration have been shown to control the outcomes of Fc ϵ RI engagement in not just quantitative, but also qualitative, fashions¹⁹. Specifically, low antigen concentration or valency will activate only positive Fc ϵ RI signaling pathways, while high antigen valency or concentration will preferentially engage negative signaling components downstream of Fc ϵ RI. This is due to activity of the Src family kinase Lyn as a positive and/or negative regulator of Fc ϵ RI signaling at low or high antigen valency, respectively¹⁹.

We stimulated BMMCs with low (DNP₅-BSA) or high (DNP₃₂-HSA) potency antigens in the presence of Tim4-Fc or isotype control and assessed whether Tim-1 ligation could contribute to receptor signaling intensity. Thus, at high antigen valency, which also activates negative feedback of antigen receptor signaling, Tim-4 was able to maintain high IL-6 production but not at low antigen valency that induces robust antigen receptor signaling (Figure 1E–F). Specifically, increasing the amount of Tim-4 further promoted cytokine secretion under high valency antigen stimulation, i.e. under conditions where the negative signaling loop is triggered. To exclude the possibility that Fcγ receptor binding may interfere with Tim1-Tim4 interaction, we compared IL-6 release by BMMCs, with or without addition of Fc blocking antibody, and found no differences, at least at the concentration of Tim4-Fc used throughout this study (5 μg/ml). These findings indicate that Tim-1 ligation can modulate the intensity of the antigen-induced positive FcεRI signaling pathways and may be able to bypass the negative feedback signaling loop controlled by Lyn.

Tim-1 antibodies do not have significant effects on IgE/Ag-mediated mast cell activation

Several antibodies against Tim-1 have been tested and showed no effects on either IgE/Ag-induced mast cell degranulation or cytokine production¹⁶. Of significance are the mAbs 3B3 and RMT1-10, which have been termed “agonistic” and “antagonistic” antibodies, respectively, due to their ability to enhance or inhibit effector T cell activation²⁰. Similarly, we did not observe any dose-dependent effects of 3B3, RMT1-10 or the IgV domain-binding mAb 5F12 on levels of IL-6 and TNF-α secreted by IgE-sensitized and Ag-stimulated BMMCs (Figure 2A–D). We examined several other antibodies, generated against the BALB/c allele of Tim-1, which were shown to either exacerbate or ameliorate Th2-dependent OVA-induced lung inflammation in mice⁷. Specifically, mAbs 1H8 and 3A2 bind to distinct epitopes near an N-linked glycosylation site in the stalk region and have agonistic and antagonistic activity, respectively. The mAb 4A2 binds to the IgV domain of Tim-1 and reduces lung inflammation and pathology⁷. However, aside from 4G8, we did not detect significant binding of these antibodies to BALB/c Tim-1. While 4G8 recognized surface Tim-1, it did not alter Ag-mediated cytokine production in mast cells (Figure 2E). Even though these antibodies were raised against the BALB/c allele of Tim-1, we also observed binding of 4G8 to C57BL/6 Tim-1 (Figure 2F). There was a small, although statistically insignificant, increase in IL-6 production when 4G8 was used in co-stimulation with FcεRI crosslinking by IgE/Ag (Figure 2F). These results further support the concept that the effects of antibody modulation of Tim-1 are cell-type and context-dependent^{7,16}.

Tim-1 cytoplasmic tyrosine is required for enhancement of transcriptional activation

We previously demonstrated that transient expression of Tim-1 co-stimulated TCR/CD28-mediated transcriptional activation of IL-4 and IFN-γ production and NF-AT/AP1-dependent transcription. This co-stimulatory activity was dependent on tyrosine 276 in the Tim-1 cytoplasmic tail⁶. Similarly, ectopic expression of Tim-1 on MC/9 mast cells was able to enhance IgE/Ag-stimulated NF-κB transcriptional activation (Figure 3A). This enhancement was abrogated when the cytoplasmic tail of Tim-1 was deleted or when a

tyrosine-phenylalanine mutant (Y276F) was used (Figure 3A). Polymorphisms in Tim-1 have been associated with differential responses to OVA-induced allergic asthma². We found that both isoforms of Tim-1 (BL/6 and BALB/c) could significantly enhance activation of an NF-κB transcriptional reporter to a comparable extent (Figure 3B). Consistent with findings in T cells and effects on mast cell cytokine production, transient expression of Tim-1 also up-regulated NF-AT/AP1 and IL-6 promoter activation, in a tyrosine phosphorylation-dependent manner (Figure 3C–D). Furthermore, using IL-6 promoter deletion constructs, we showed that Tim-1 mediated enhancement of transcriptional activation and subsequent production of IL-6 through activation of NF-κB and AP-1 transcription factors (Figure 3E). Unlike Tim-4 crosslinking of Tim-1, addition of anti-FLAG antibody could not further promote reporter activity, suggesting either that Tim-1 may have other ligands on MC/9 mast cells or that Tim-1 can homo-dimerize after ectopic expression, via its heavily glycosylated mucin domain, leading to downstream signaling.

Tim-1 mucin domain is not required for Tim4-mediated enhancement of mast cell cytokine production

Our findings thus far suggest that the Tim1-Tim4 interaction augments FcεRI signaling itself, rather than acting through a parallel pathway, since Tim-4 treatment alone does not induce any detectable cytokine production or degranulation. While the Tim1-Tim4 interaction has been attributed primarily to the IgV domain, Tim-4 has also been proposed to bind to the Tim-1 mucin domain¹⁰. Intriguingly, the genetic linkage of Tim-1 to allergies and asthma is associated with polymorphisms in the mucin domain. Using a mutant mouse lacking only the Tim-1 mucin domain (Tim-1^{Δmucin})²¹, we determined whether the Tim-1 mucin domain is necessary to relay the co-stimulatory effects of Tim-4 binding. We noted no obvious defects in mast cell development or maturation, when BMMC were generated from Tim-1^{Δmucin} bone marrow. Thus, WT and Tim-1^{Δmucin} BMMCs expressed comparable levels of surface Tim-1, based on staining with IgV-binding Tim-1 antibodies (Figure 4A). Tim-1^{Δmucin} BMMCs exhibited a similar extent of degranulation in response to antigen stimulation, compared to WT BMMCs, which was not altered by Tim-1 ligation (Figure 4B–C). Next, we examined the ability of Tim-1^{Δmucin} BMMCs to secrete cytokines in response to IgE/Ag. Tim-1^{Δmucin} mast cells appeared to respond normally to antigen stimulation, and also to Tim4-mediated co-stimulation (Figure 4D). Using different batches of BMMCs over the course of multiple experiments, we were not able to consistently observe any major difference between WT and Tim-1^{Δmucin} BMMCs. We did observe some variation in the amount of IL-6 produced by different batches of BMMCs, but this appeared to be largely due to the relative maturation status of the cells (Figure 4E–H). These results indicated that the mucin domain of Tim-1 is not required for normal mast cell responses and also that Tim-4-mediated mast cell activation does not appear to involve the mucin domain of Tim-1, but rather its IgV domain.

Tim-1 enhances Ag-activated phosphorylation of ribosomal protein S6

Next, we assessed the potential signaling pathways utilized by Tim1-Tim4 interaction downstream of FcεRI signaling to upregulate mast cell cytokine production. Using a Nur77GFP reporter

Figure 2. Tim-1 antibodies did not significantly alter IgE/Ag-mediated mast cell cytokine production compared to ligation by Tim4-Fc.

BL/6 or BALB/c BMMCs (1×10^6) as indicated were sensitized with IgE overnight and stimulated with DNP₃₂-HSA in the presence of isotype control or monoclonal antibodies against Tim-1 3B3 (A–B), RMT1-10 (C–D), 3A2, 4A2, 4B2, 4G8, 1H9 (E) for six hours. The indicated antibodies were incubated with BALB/c BMMCs for 30 minutes on ice followed by anti-rat IgG-Alexa-647 secondary antibody, prior to flow cytometry analysis (E). Culture supernatants were analyzed for IL-6 and TNF-α by ELISA. BL/6 BMMCs were incubated with 4G8, 4A2 and 5D1 antibodies followed by anti-rat IgG-Alexa 647 secondary antibody prior to flow cytometry analysis (F). BL/6 BMMCs sensitized with IgE overnight and stimulated with DNP₃₂-HSA together with either isotype control or the indicated antibodies for six hours prior to IL-6 measurement by ELISA (F). Results are representative of three (A–D) and two (E–F) independent experiments performed in duplicates.

Figure 3. Tim1-mediated enhancement of transcriptional activation is dependent on a tyrosine on its cytoplasmic tail. MC/9 mouse mast cells were transfected with empty vector (pCDEF3), BL/6 or BALB/c Tim-1 (full length (FL)), BL/6 Tim-1 lacking the cytoplasmic region (Δcyto) or full length Tim-1 (BL/6) with tyrosine to phenylalanine mutated at tyrosine 276 (Y276). Transfected cells were stimulated with 0.5 μg/ml IgE plus either 30 ng/ml or 100 ng/ml DNP₃₂-HSA, with or without addition of anti-FLAG antibody for six hours. MC/9 mast cells were co-transfected NF-κB (A–B), NFAT/AP1 (C), and IL-6 (D) luciferase reporters. MC/9 mast cells were transfected with full length BL/6 Tim-1 along with indicated IL-6 luciferase reporters and stimulated as described (E). Results are representative of three independent experiments performed in triplicate. *p<0.05, **p<0.005, ****p<0.00005.

Figure 4. Tim-1 mucin domain is not required for Tim4-mediated enhancement of cytokine production in IgE/Ag-stimulated Tim-1 Δ mucin BMMCs. Tim-1 surface expression and maturity of WT and Tim-1 Δ mucin BMMCs were determined by FcεRI and c-kit staining (A). WT and Tim-1 Δ mucin BMMCs were sensitized overnight with IgE and stimulated with 10 ng/ml, 50 ng/ml, 100 ng/ml DNP₃₂-HSA, and 5 μg/ml Tim4-Fc. Mast cell degranulation was measured by Annexin V and Lysotracker staining (B–C). Results are average of three (B) and two (C) independent experiments. Culture supernatants were collected and analyzed for IL-6 by ELISA (D). Using six separate batches of BMMCs. WT and Tim-1 Δ mucin BMMCs were stimulated with indicated amount of antigen with either 5 μg/ml isotype control Fc (iso) or Tim4-Fc for six hours (E–H). Results are comparison between WT and Tim-1 Δ mucin BMMCs from six independent experiments using six separate batches of BMMCs. *p < 0.05.

mouse, we previously showed that unlike the related family member Tim-3, engagement of Tim-1 did not enhance FcεRI signal intensity, thereby showing that Tim-1 cross-linking does not augment antigen receptor-proximal signaling¹⁸. We moved on to explore signaling pathways both proximal and distal to the FcεRI complex, for any effects of Tim-1. Thus, the Zap70-related kinase Syk is an FcεRIγ-associated activator integral to activation of LAT, SLP76, PLC-γ and other adaptor molecules essential for signal transduction downstream of FcεRI²². Phosphorylation of Syk was not further increased by Tim-4 (Figure 5A). Similarly, we observed robust phosphorylation of ERK and Akt upon IgE/Ag-induced activation

that was not affected by Tim-1 engagement (Figure 5B and data not shown). These results demonstrate that MEK/ERK and PI3K/Akt pathways are not involved in enhancement of Ag-mediated mast cell function by Tim-1, even though we observed that phosphorylation of Tim-1 cytoplasmic tail by TCR activation led to recruitment of p85 subunit of PI3K⁸. Nevertheless, we did detect a significant increase in phosphorylation of ribosomal protein S6, an important target of the PI3K/mTOR pathway regulating cell growth, survival, metabolism, and protein synthesis in mast cells²³. Mast cells exhibited robust phosphorylation of S6 (~80% of BMMC) one hour post-Ag stimulation, which did not increase further with Tim-4

Figure 5. Tim-1 ligand Tim4-Fc enhances mast cell cytokine production by sustaining ribosomal protein S6 phosphorylation upon IgE/Ag activation. BL/6 BMMCs were sensitized overnight with IgE and stimulated with DNP₃₂-HSA in the presence of isotype control or Tim4-Fc for the indicated time. Syk phosphorylation (Y519/520) (A), pErk (T202/Y204) (B), and pS6 (S235/236) (C) were analyzed by phospho-flow cytometry. Results are average of two independent experiments (A–B) or three independent experiments (C). *p<0.05, ***p<0.0005.

addition. However, Tim-4 treatment was able to maintain a significant percentage of pS6-positive BMMCs for as long as four hours, even as the Ag-triggered signal returned to basal levels (Figure 5C). Overall, these results support a positive role of Tim-1 activation by Tim-4 to sustain mTOR-dependent mast cell metabolism and protein synthesis, leading to enhanced cytokine production.

Discussion

Mast cells constitutively express high levels of cell-surface Tim-1, a molecule with co-stimulatory effects on many immune cell types, but with unclear mechanisms of action. Here we demonstrate that Tim-1 is a positive regulator of mast cell activation and cytokine production. Similar to our findings on the effects of Tim-3 on mast cells¹⁸, Tim-1 expression alone could promote IgE/Ag-mediated NF- κ B and NF-AT/AP1 transcriptional activation, without additional cross-linking antibodies or exogenous ligands. Tim-4 is a ligand for Tim-1, but the lack of Tim-4 expression on mast cells makes it an unlikely explanation for this particular role of Tim-1 in mast cells. Tim-1 can also bind PS on apoptotic cells²⁴ or PS transiently exposed on degranulating mast cells, either of which could potentially contribute to enhance Tim-1 signaling, although whether PS binding to Tim-1 can lead to mast cell activation is still unknown. Tim-1 has also been reported to bind LMIR5/CD300b, a DAP12-coupled activating receptor expressed on myeloid cells²⁵. Thus, stimulation with TIM1-Fc was able to induce LMIR5-mediated ERK activation in mast cells, suggesting that LMIR5 is another potential endogenous ligand of Tim-1, driving the enhancement of transcriptional response. Finally, Tim-1 may homodimerize through its heavily glycosylated mucin domain, leading to its phosphorylation and downstream function. Regardless of its mode of activation, we showed that Tim-1 co-stimulation is dependent on the tyrosine phosphorylation motif of Tim-1 cytoplasmic tail as mutation of tyrosine 276 rendered Tim-1 unable to mediate its co-stimulatory function. The Src kinase Fyn has been shown to phosphorylate Tim-1 in a B cell line²⁶. We showed that the Tim-1 cytoplasmic tail is phosphorylated upon TCR stimulation in an Lck-dependent manner and can recruit p85 binding⁸. Therefore, Src family kinases like Lyn, Fyn or Hck are potential facilitators of Tim-1 phosphorylation upon IgE/Ag activation.

Another aim of this study was to determine how Tim-1 cross-linking by antibodies or ligands could modulate mast cell activation. Unlike in T cells or *in vivo* experiments, mast cells did not respond to Tim-1 antibody treatment, as none of the antibodies tested elicited a change in mast cell degranulation or cytokine production. On the other hand, Tim-4 treatment consistently enhanced IgE/Ag-mediated cytokine production but not degranulation, which may be a time- and/or signal intensity-dependent effect. Tim-4 was reported to have bimodal effects, either enhancing or inhibiting T cell proliferation, depending on anti-CD3/CD28 concentrations¹⁰. This bimodal regulation was later reported to be inhibitory for naïve T cells, which do not express Tim-1, and co-stimulatory for activated T cells, suggesting that Tim-4 either binds to an unknown ligand expressed only on naïve T cells or that Tim-4 has a higher affinity for Tim-1 expressed on activated T cells²⁷. In addition, Tim-4 can bind to naïve T cells that do not express Tim-1 and inhibit Th17 differentiation²⁸. This effect was shown to be independent of Tim-1 activity, since addition of Tim-1 blocking antibody, presumably to

block the Tim1:Tim4 interaction, could not rescue Tim4-mediated inhibition²⁸. In contrast to such ligand-dependent effects observed on T cells, Tim-4 co-stimulates IgE/Ag-mediated mast cell activation by cross-linking Tim-1. Using low and high valency antigens to engage the positive and negative signaling pathways of Fc ϵ RI, respectively, we showed that Tim-4 could enhance mast cell cytokine production in both settings. Specifically, Tim-4 co-stimulated cytokine release in a dose-dependent manner, under both high and low valency antigen stimulation. These results imply that Tim-4 contributes to Fc ϵ RI signaling intensity and/or duration, and may potentially override negative feedback signals linked primarily to Lyn-mediated phosphatase activation. Together with findings that Tim-4 alone does not induce cytokine production in mast cells, our results demonstrate that Tim-1 signaling interfaces with common effector molecules downstream of Fc ϵ RI signaling, rather than acting through a parallel pathway, to enhance mast cell functions.

To determine whether Tim-1 plays a positive or negative regulatory role in mast cells, we first attempted siRNA-mediated knockdown of Tim-1 protein in BMMCs but were unsuccessful in obtaining efficient Tim-1 reduction. Furthermore, two separate strains of Tim-1-deficient mice showed relatively unaltered IgE production and AHR development in an OVA-induced mouse model of asthma, even though one study did observe higher type 2 and Th17 cytokine production in Tim-1 knockout (KO) mice^{26,29}. On the other hand, the importance of the Tim-1 mucin domain has been demonstrated in T cell activation, differentiation, trafficking, and effector function in autoimmunity and airway inflammation^{28,30}. It is also essential to regulatory B cell maintenance, signaling, transplant tolerance and induction of systemic autoimmunity^{14,15,21}. Thus, we examined whether the Tim-1 mucin domain regulates mast cell activity, particularly in the context of Tim-4 treatment. Contrary to the effects seen in B and T cells, the Tim-1 mucin domain is dispensable for mast cell activity, as mast cell degranulation and cytokine release remain intact in the absence of the mucin domain. It is worth noting that Tim-1 ^{Δ mucin} BMMCs were actually able to secrete more cytokine than WT BMMCs in some instances. However, after testing six different batches of WT and Tim-1 ^{Δ mucin} BMMCs, it appeared that any differences observed were due to the maturation status of BMMCs and their Fc ϵ RI surface expression, rather than any direct effect of deletion of the Tim-1 mucin domain. While our study focused on bone marrow-derived mast cells, absence of the Tim-1 mucin domain may nonetheless affect trafficking and/or differentiation of other mast cell types in their respective tissue microenvironments *in vivo*. Tim1-Tim4 interaction is thought to occur mostly through the IgV domains of the respective proteins, although there is evidence that Tim-4 may also bind to the Tim-1 mucin domain¹⁰. We showed that Tim-4 mediated co-stimulation of mast cell function occurred independent of the mucin domain. It remains to be determined, in the absence of the Tim-1 mucin domain, whether Tim-4 has other unknown ligands on mast cells that can mediate this enhancement.

We also examined the signaling pathways leading to enhanced transcriptional activation and cytokine production by Tim-1 and Ag co-stimulation in mast cells. Phosphorylation of Syk was not altered by Tim-4 treatment at the time points we examined. This is consistent with our finding that the Tim1-Tim4 interaction did not promote Ag-stimulated Fc ϵ RI signaling intensity, using mast cells

from a Nur77^{GFP} mouse model¹⁸. Syk is phosphorylated on multiple tyrosines by either auto-phosphorylation or trans-phosphorylation by Lyn, resulting in positive or negative regulation, respectively, of Ag-mediated FcεRI signaling^{31–33}. Since we only examined tyrosines 519 and 520 in the kinase loop, which are sites of Syk auto-phosphorylation, it is possible that other tyrosine phosphorylation sites may be affected by Tim-1. One particular site of interest is tyrosine 346 in the linker region, which is important for PLC-γ1 binding and phosphorylation³⁴. Aside from positive signaling pathways, the relevant negative signaling pathways should be investigated for potential down-regulation by Tim-1 engagement. Thus, a particular FcεRI proximal phosphatase of interest is the Src homology-2-containing signaling protein (SHIP), which has been implicated in regulation of IgE/Ag-induced IL-6 production through inhibition of NF-κB activity, both of which are enhanced by Tim-1 cross-linking in our study³⁵.

In a previous study, Tim-4/CD3/CD28-coated beads enhanced phosphorylation of Erk and Akt in CD4 T cells⁹. These results were not observed in previously study using both BMMCs and peritoneal mast cells (PMCs)¹⁶. Similarly, we did not observe similar effect with soluble Tim-4 addition in Ag-mediated FcεRI aggregation at the peak of antigen stimulation or when signals returned to basal. It is possible that Tim-4 signals are cell-type specific or that mast cells require more robust aggregation of Tim-1 at the time of antigen stimulation to induce substantial effects. While phosphorylation of Akt was not affected, ribosomal protein S6 was significantly enhanced upon Tim-4 treatment. Specifically, Tim-1 cross-linking enhanced and sustained IgE/Ag-induced S6 phosphorylation, which correlates with enhanced cytokine production. Ribosomal protein S6 is a downstream effector of PI3K/mTOR signaling, and as such is essential for mast cell survival, proliferation, metabolism and protein synthesis. MALT1 and BCL10, members of the Carma1-MALT1-Bcl10 (CBM) complex, are essential regulators of FcεRI-induced mast cell activation by selectively up-regulating NF-κB-dependent cytokine production without affecting degranulation and leukotriene synthesis³⁶. We previously identified a Carma1-MALT1-dependent activation of mTOR signaling after TCR engagement, leading to phosphorylation of S6 and another mTOR substrate 4E-BP1³⁷. Thus, Tim-1 may preferentially engage the MALT1-Bcl10 pathway to modulate mTOR signaling and NF-κB responses without affecting FcεRI-proximal signaling. Consequently, further studies are needed to address whether Tim1-Tim4 interaction promotes mast cell metabolic responses and protein synthesis as well as whether the specific Tim-1 targets in this pathway leading to effector functions.

Taken together, our findings provide further evidence that Tim-1 signaling can promote cytokine production in IgE/Ag-activated mast cells. This is in line with a co-stimulatory role for Tim-1 in T, B and NKT cells, both *in vitro* and *in vivo*. Contrary to their previously described effects on these cell types, Tim-1 antibodies did not regulate mast cell degranulation and cytokine production in our hands. Nevertheless, Tim-1 ligation by Tim-4 consistently enhanced mast cell cytokine production, and this effect was not affected by loss of the Tim-1 mucin domain. We also showed, for the first time, that unlike in regulatory B cells, the Tim-1 mucin domain is dispensable for mast cell effector function. Mast cells play diverse roles in hypersensitivity, allergic and, as has been increasingly appreciated, non-allergic diseases¹⁷. Tim-1 blockade or cross-linking by known ligands and antibodies has been shown to ameliorate or exacerbate allergic lung inflammation *in vivo*. Therefore, manipulation of Tim-1 activity on mast cells, particularly modulation of the Tim1-Tim4 interaction, could be a novel therapeutic target to control allergic and autoimmune disease.

Data availability

F1000Research: Dataset 1. Raw data for **Figure 1–Figure 5** in ‘Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies’, [10.5256/f1000research.8132.d114870](https://doi.org/10.5256/f1000research.8132.d114870)⁴⁰

Author contributions

LPK conceived the study. BLP and LPK designed the experiments. All experiments were carried out by BLP. Data analysis and interpretation were performed by BLP and LPK. BLP wrote the manuscript, with editorial assistance from LPK.

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by PHS grant R56AI067544 to LPK.

I confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

We thank V. Kuchroo for providing Tim-1 antibodies and Tim4-Fc recombinant protein. We also thank V. Kuchroo and D. Rothstein for the Tim-1^{Δmucin} mice.

References

- Feigelstock D, Thompson P, Mattoo P, *et al.*: **The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor.** *J Virol.* 1998; **72**(8): 6621–8.
[PubMed Abstract](#) | [Free Full Text](#)
- McIntire JJ, Umetsu SE, Akbari O, *et al.*: **Identification of *Tapr* (an airway hyperreactivity regulatory locus) and the linked *Tim* gene family.** *Nat Immunol.* 2001; **2**(12): 1109–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lee J, Phong B, Eglhoff AM, *et al.*: **TIM polymorphisms—genetics and function.** *Genes Immun.* 2011; **12**(8): 595–604.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- McIntire JJ, Umetsu SE, Macaubas C, *et al.*: **Immunology: hepatitis A virus link to atopic disease.** *Nature.* 2003; **425**(6958): 576.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Umetsu SE, Lee WL, McIntire JJ, *et al.*: **TIM-1 induces T cell activation and inhibits the development of peripheral tolerance.** *Nat Immunol.* 2005; **6**(5): 447–54.
[PubMed Abstract](#) | [Publisher Full Text](#)

6. de Souza AJ, Oriss TB, O'Malley K J, *et al.*: **T cell Ig and mucin 1 (TIM-1) is expressed on *in vivo*-activated T cells and provides a costimulatory signal for T cell activation.** *Proc Natl Acad Sci U S A*. 2005; **102**(47): 17113–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Sizing ID, Bailly V, McCoon P, *et al.*: **Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses.** *J Immunol*. 2007; **178**(4): 2249–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. de Souza AJ, Oak JS, Jordanhazy R, *et al.*: **T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase.** *J Immunol*. 2008; **180**(10): 6518–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Rodriguez-Manzanet R, Meyers JH, Balasubramanian S, *et al.*: **TIM-4 expressed on APCs induces T cell expansion and survival.** *J Immunol*. 2008; **180**(7): 4706–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Meyers JH, Chakravarti S, Schlesinger D, *et al.*: **TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation.** *Nat Immunol*. 2005; **6**(5): 455–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Binné LL, Scott ML, Rennett PD: **Human TIM-1 associates with the TCR complex and up-regulates T cell activation signals.** *J Immunol*. 2007; **178**(7): 4342–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Han WK, Bailly V, Abichandani R, *et al.*: **Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.** *Kidney Int*. 2002; **62**(1): 237–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Kim HY, Chang YJ, Chuang YT, *et al.*: **T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death.** *J Allergy Clin Immunol*. 2013; **132**(2): 414–25.e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Yeung MY, Ding Q, Brooks CR, *et al.*: **TIM-1 signaling is required for maintenance and induction of regulatory B cells.** *Am J Transplant*. 2015; **15**(4): 942–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Ding Q, Yeung M, Camirand G, *et al.*: **Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice.** *J Clin Invest*. 2011; **121**(9): 3645–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Nakae S, Iikura M, Suto H, *et al.*: **TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells.** *Blood*. 2007; **110**(7): 2565–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. da Silva EZ, Jamur MC, Oliver C: **Mast cell function: a new vision of an old cell.** *J Histochem Cytochem*. 2014; **62**(10): 698–738.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Phong BL, Avery L, Sumpter TL, *et al.*: **Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation.** *J Exp Med*. 2015; **212**(13): 2289–304.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Xiao W, Nishimoto H, Hong H, *et al.*: **Positive and negative regulation of mast cell activation by Lyn via the FcεRI. J Immunol. 2005; **175**(10): 6885–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)**
20. Xiao S, Najafian N, Reddy J, *et al.*: **Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function.** *J Exp Med*. 2007; **204**(7): 1691–702.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Xiao S, Brooks CR, Zhu C, *et al.*: **Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice.** *Proc Natl Acad Sci U S A*. 2012; **109**(30): 12105–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Kambayashi T, Koretzky GA: **Proximal signaling events in Fc epsilon RI-mediated mast cell activation.** *J Allergy Clin Immunol*. 2007; **119**(3): 544–52; quiz 53–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Kim MS, Kuehn HS, Metcalfe DD, *et al.*: **Activation and function of the mTORC1 pathway in mast cells.** *J Immunol*. 2008; **180**(7): 4586–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Kobayashi N, Karisola P, Peña-Cruz V, *et al.*: **TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells.** *Immunity*. 2007; **27**(6): 927–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Yamanishi Y, Kitaara J, Izawa K, *et al.*: **TIM1 is an endogenous ligand for LMR5/CD300b: LMR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury.** *J Exp Med*. 2010; **207**(7): 1501–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Curtiss ML, Hostager BS, Stepniak E, *et al.*: **Fyn binds to and phosphorylates T cell immunoglobulin and mucin domain-1 (Tim-1).** *Mol Immunol*. 2011; **48**(12–13): 1424–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Mizui M, Shikina T, Arase H, *et al.*: **Bimodal regulation of T cell-mediated immune responses by TIM-4.** *Int Immunol*. 2008; **20**(5): 695–708.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Cao W, Ryan M, Buckley D, *et al.*: **Tim-4 inhibition of T-cell activation and T helper type 17 differentiation requires both the immunoglobulin V and mucin domains and occurs via the mitogen-activated protein kinase pathway.** *Immunology*. 2011; **133**(2): 179–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Barlow JL, Wong SH, Ballantyne SJ, *et al.*: **Tim1 and Tim3 are not essential for experimental allergic asthma.** *Clin Exp Allergy*. 2011; **41**(7): 1012–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Angiari S, Donnarumma T, Rossi B, *et al.*: **TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity.** *Immunity*. 2014; **40**(4): 542–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Zhang J, Kimura T, Siraganian RP: **Mutations in the activation loop tyrosines of protein tyrosine kinase Syk abrogate intracellular signaling but not kinase activity.** *J Immunol*. 1998; **161**(8): 4366–74.
[PubMed Abstract](#)
32. Sanderson MP, Gelling SJ, Rippmann JF, *et al.*: **Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcεRI-activated RBL-2H3 basophilic cells.** *Cell Immunol*. 2010; **262**(1): 28–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Sada K, Zhang J, Siraganian RP: **Point mutation of a tyrosine in the linker region of Syk results in a gain of function.** *J Immunol*. 2000; **164**(1): 338–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Law CL, Chandran KA, Sidorenko SP, *et al.*: **Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk.** *Mol Cell Biol*. 1996; **16**(4): 1305–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Kalesnikoff J, Baur N, Leitges M, *et al.*: **SHIP negatively regulates IgE + antigen-induced IL-6 production in mast cells by inhibiting NF-kappa B activity.** *J Immunol*. 2002; **168**(9): 4737–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Klemm S, Gutermuth J, Hüttner L, *et al.*: **The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation.** *J Exp Med*. 2006; **203**(2): 337–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Hamilton KS, Phong B, Corey C, *et al.*: **T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10.** *Sci Signal*. 2014; **7**(329): ra55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Demo SD, Masuda E, Rossi AB, *et al.*: **Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay.** *Cytometry*. 1999; **36**(4): 340–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Kane LP, Shapiro VS, Stokoe D, *et al.*: **Induction of NF-kappaB by the Akt/PKB kinase.** *Curr Biol*. 1999; **9**(11): 601–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Phong B, Kane L: **Dataset 1 in: Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies.** *F1000Research*. 2016.
[Data Source](#)

Open Peer Review

Current Peer Review Status: ? ✓

Version 1

Reviewer Report 23 June 2016

<https://doi.org/10.5256/f1000research.8748.r14555>

© 2016 Wilson B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bridget S Wilson

Department of Pathology, University of New Mexico, Albuquerque, NM, Mexico

The TIM-1 protein has been implicated in regulation of T cells, NKT cells and regulatory B cells. Here, the focus is on mast cells, where Tim-1 has been shown to be constitutively expressed and is believed to have a co-stimulatory function for NF-κB and NFAT/AP1 transcription and cytokine production.

A few points would be helpful to address in the final version of the manuscript.

1. Prior work has shown that Tim-1 recognizes phosphatidylserine on apoptotic cells and that the mucin domain is important for this binding. Since the data presented here show that annexin-binding (which detects PS) is upregulated as a function of mast cell degranulation, the Tim-1 mucin domain might mediate homotypic interactions between recently degranulated cells. Is there evidence that this occurs (microscopy images or flow-based measures?) If this is a mechanism to cluster Tim1 for activation, it will be in a "synapse"-like setting and would support a post-degranulation, delayed co-stimulatory signal. As mentioned below, Tim-4 mediated activation *in vivo* is probably in a synapse setting too, so there seems like a missed opportunity here.
2. This study relies a lot on exogenous agents (Tim4-Fc, antibodies) to make conclusions about the role of Tim-1 signaling. This is fine as an experimental approach, but can confound the conclusions reached about the role of the mucin domain. In other words, if one bypasses the mucin domain by activating with Tim4-Fc, it does not necessarily mean that ligations mediated via the mucin domain does not mediate signaling in another setting. I find, in general, that the emphasis on this result is overstated/over-discussed as a physiological relevant finding. It provides more insight on the structural features of Tim-1, which can apparently be activated by crosslinking (ie antibodies) or by binding to another Tim (Tim4) presented on another cell... and possibly when PS, presented on another mast cell or an apoptotic cell in the inflammatory microenvironment, clusters Tim-1 via the mucin domain.

In keeping with this, I think the discussion could be shortened and simplified. For example, this text could be omitted or reworded:

"Thus, we examined whether the Tim-1 mucin domain regulates mast cell activity, particularly in the context of Tim-4 treatment. Contrary to the effects seen in B and T cells, the Tim-1 mucin domain is dispensable for mast cell activity, as mast cell degranulation and cytokine release remain intact in the absence of the mucin domain. It is worth noting that Tim-1 Δ mucin BMMCs were actually able to secrete more cytokine than WT BMMCs in some instances. However, after testing six different batches of WT and Tim-1 Δ mucin BMMCs, it appeared that any differences observed were due to the maturation status of BMMCs and their Fc[epsilon]RI surface expression, rather than any direct effect of deletion of the Tim-1 mucin domain."

3. This group has opted to use SPE-7 (anti-DNP) IgE to prime the BMMC. Since this is a cytokinergic IgE, it could be good to confirm that the essential findings of co-stimulation also occur when using a non-cytokinergic (anti-DNP) IgE ...perhaps the Liu IgE.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response (F1000Research Advisory Board Member) 30 Jun 2016

Larry Kane, University of Pittsburgh School of Medicine, Pittsburgh, USA

1. *Prior work has shown that Tim-1 recognizes phosphatidylserine on apoptotic cells and that the mucin domain is important for this binding. Since the data presented here show that annexin-binding (which detects PS) is upregulated as a function of mast cell degranulation, the Tim-1 mucin domain might mediate homotypic interactions between recently degranulated cells. Is there evidence that this occurs (microscopy images or flow-based measures?) If this is a mechanism to cluster Tim1 for activation, it will be in a "synapse"-like setting and would support a post-degranulation, delayed co-stimulatory signal. As mentioned below, Tim-4 mediated activation is probably in a synapse setting too, so there seems like a missed opportunity here.*

- The reviewer raises an interesting point regarding the regulation of Tim-1 by PS on degranulating mast cells (although to our knowledge, the Tim1:PS interaction mainly occurs through the Tim-3 IgV domain). We have not yet been able to image Tim-1 during mast cell activation, but feel that this would be an interesting topic for future exploration.

2. *This study relies a lot on exogenous agents (Tim4-Fc, antibodies) to make conclusions about the role of Tim-1 signaling. This is fine as an experimental approach, but can confound the conclusions reached about the role of the mucin domain. In other words, if one bypasses the mucin domain by activating with Tim4-Fc, it does not necessarily mean that ligations mediated via the mucin domain does not mediate signaling in another setting. I find, in general, that the emphasis on this result is overstated/over-discussed as a physiological relevant finding. It provides more insight on the structural features of Tim-1, which can apparently be activated by crosslinking (ie antibodies) or by binding to another Tim (Tim4) presented on another cell... and possibly when PS, presented on another mast*

cell or an apoptotic cell in the inflammatory microenvironment, clusters Tim-1 via the mucin domain.

- This is a fair point. We have modified the discussion of these results in line with this comment and the one below.

3. *In keeping with this, I think the discussion could be shortened and simplified. For example, this text could be omitted or reworded:*

"Thus, we examined whether the Tim-1 mucin domain regulates mast cell activity, particularly in the context of Tim-4 treatment. Contrary to the effects seen in B and T cells, the Tim-1 mucin domain is dispensable for mast cell activity, as mast cell degranulation and cytokine release remain intact in the absence of the mucin domain. It is worth noting that Tim-1 d.mucin BMMCs were actually able to secrete more cytokine than WT BMMCs in some instances. However, after testing six different batches of WT and Tim-1 d.mucin BMMCs, it appeared that any differences observed were due to the maturation status of BMMCs and their Fc[epsilon]RI surface expression, rather than any direct effect of deletion of the Tim-1 mucin domain."

- This is a good suggestion – we have now edited the Discussion, to make it more readable, and as a result it has been shortened by about one page.

4. *This group has opted to use SPE-7 (anti-DNP) IgE to prime the BMMC. Since this is a cytokinergic IgE, it could be good to confirm that the essential findings of co-stimulation also occur when using a non-cytokinergic (anti-DNP) IgE ...perhaps the Liu IgE.*

- We have only used the commercially available, and widely employed, SPE-7 IgE in our studies. We agree that branching out to other IgE's would be an interesting avenue for future follow-up exploration.

Competing Interests: No competing interests were disclosed.

Reviewer Report 15 March 2016

<https://doi.org/10.5256/f1000research.8748.r12697>

© 2016 August A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Avery August

Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA

There are a few issues that the authors should address as they refine the presentation of this work as detailed below:

1. The authors should refer to the data in Figure 1A, the characterization of the TIM-4-Fc reagent and expression of TIM-1 on the surface of these mast cells.
2. Since IgE alone has been shown to affect mast cell survival, does TIM-4/TIM-1 affect the

mast cell response to IgE alone?

3. In figure 1E, the graph looks as if there is production of IL-6 in the absence of IgE (third bar from the left). Is this correct?
4. The location of the flag tag on TIM-1 should be described by the authors.
5. Do the antibodies against TIM-1 affect the ability of TIM-4 to enhance cytokine production?
6. The reference to a small although statistically insignificant increase in IL6 when 4G8 was used is not appropriate to say, since the change is not significant, and not any larger than other changes that are not remarked upon by the authors. This statement should be modified.
7. In experiments where TIM-1 is overexpressed in the MC/9 cell line, what is the ligand for the transfected TIM-1?
8. Is calcium signaling affected by TIM-4/Tim-1 interaction? Is activation of Btk affected given the potential role of PI3K downstream of TIM-1?
9. The statement in the 6th line of the discussion starting with "Tim-1 expression alone could promote IgE/Ag-mediated NF- κ B and NF-AT/AP1 transcriptional activation..." should be qualified that this is in MC/9 cells, which may not behave like primary mast cells.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response (F1000Research Advisory Board Member) 30 Jun 2016

Larry Kane, University of Pittsburgh School of Medicine, Pittsburgh, USA

1. *The authors should refer to the data in Figure 1A, the characterization of the TIM-4-Fc reagent and expression of TIM-1 on the surface of these mast cells.*
 - This is now added to the Results, with an extra description of the Tim4-Fc in the methods
2. *Since IgE alone has been shown to affect mast cell survival, does TIM-4/TIM-1 affect the mast cell response to IgE alone?*
 - We did not test the IgE+Tim4-Fc condition ourselves but a previous paper from Galli and colleagues (ref. 16 in the manuscript) showed that IgE + rmTim-4 did not trigger degranulation, cytokine production, or prevent mast cell apoptosis from IL-3 withdrawal.
3. *In figure 1E, the graph looks as if there is production of IL-6 in the absence of IgE (third bar from the left). Is this correct?*

- That condition actually contains both IgE and the indicated antigen; the bar to the left of it represents cells receiving only IgE and nothing else.
4. *The location of the flag tag on TIM-1 should be described by the authors.*
- The tag is at the N-terminus. This is now stated explicitly in the Results section.
5. *Do the antibodies against TIM-1 affect the ability of TIM-4 to enhance cytokine production?*
- We did not perform any blocking experiments with the Tim-1 antibodies in the presence of Tim-4 fusion protein, but this would be an interesting future experiment.
6. *The reference to a small although statistically insignificant increase in IL6 when 4G8 was used is not appropriate to say, since the change is not significant, and not any larger than other changes that are not remarked upon by the authors. This statement should be modified.*
- This is a good point. We have now modified the sentence in question which refers to Fig. 2F in the results section to make it more accurately and clearly reflect the data.
7. *In experiments where TIM-1 is overexpressed in the MC/9 cell line, what is the ligand for the transfected TIM-1?*
- In our previous publications, we observed what appears to be constitutive activity of the transfected Tim-1 after transient transfection. We have generally interpreted this to indicate that ectopically expressed Tim-1 is oligomerizing in the absence of ligand, since it is expressed at higher than normal levels on at least a subset of the transfected cells.
8. *Is calcium signaling affected by TIM-4/Tim-1 interaction? Is activation of Btk affected given the potential role of PI3K downstream of TIM-1?*
- Given the data we have presented in the manuscript, it is indeed logical that a Tec family kinase like Btk may be a proximal target for Tim-1. We have started to address this by probing the effects of Tim-1 on PLC-g1 phosphorylation, but have not been able to observe a robust effect. However, given the limited personnel available to work currently on this project, we thought that it was important to share the results that we have obtained, which may be of interest to others studying the function of Tim-1.
9. *The statement in the 6th line of the discussion starting with "Tim-1 expression alone could promote IgE/Ag-mediated NF- κ B and NF-AT/AP1 transcriptional activation..." should be qualified that this is in MC/9 cells, which may not behave like primary mast cells.*
- This is a good point. We have now clarified in the Discussion that this was in MC/9 cells.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research